BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Trachtman H, Austin C, Lewinski M, Stahl RA. Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol 2012;8:658-69. [PMID: 22986362 DOI: 10.1038/nrneph.2012.196] [Cited by in Crossref: 129] [Cited by in F6Publishing: 113] [Article Influence: 12.9] [Reference Citation Analysis]
Number Citing Articles
1 Joseph A, Rafat C, Zafrani L, Mariani-Kurkdjian P, Veyradier A, Hertig A, Rondeau E, Mariotte E, Azoulay E. Early Differentiation of Shiga Toxin-Associated Hemolytic Uremic Syndrome in Critically Ill Adults With Thrombotic Microangiopathy Syndromes. Crit Care Med 2018;46:e904-11. [PMID: 29979220 DOI: 10.1097/CCM.0000000000003292] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
2 Cheung V, Trachtman H. Hemolytic uremic syndrome: toxins, vessels, and inflammation. Front Med (Lausanne) 2014;1:42. [PMID: 25593915 DOI: 10.3389/fmed.2014.00042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
3 Wijnsma KL, Veissi ST, de Wijs S, van der Velden T, Volokhina EB, Wagener FADTG, van de Kar NCAJ, van den Heuvel LP. Heme as Possible Contributing Factor in the Evolvement of Shiga-Toxin Escherichia coli Induced Hemolytic-Uremic Syndrome. Front Immunol 2020;11:547406. [PMID: 33414780 DOI: 10.3389/fimmu.2020.547406] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Legros N, Pohlentz G, Steil D, Müthing J. Shiga toxin-glycosphingolipid interaction: Status quo of research with focus on primary human brain and kidney endothelial cells. Int J Med Microbiol 2018;308:1073-84. [PMID: 30224239 DOI: 10.1016/j.ijmm.2018.09.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
5 Rafat C, Coppo P, Fakhouri F, Frémeaux-Bacchi V, Loirat C, Zuber J, Rondeau E. [Hemolytic and uremic syndrome and related thrombotic microangiopathies: Epidemiology, pathophysiology and clinics]. Rev Med Interne 2017;38:817-24. [PMID: 28711159 DOI: 10.1016/j.revmed.2017.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Lee BC, Mayer CL, Leibowitz CS, Stearns-Kurosawa DJ, Kurosawa S. Quiescent complement in nonhuman primates during E coli Shiga toxin-induced hemolytic uremic syndrome and thrombotic microangiopathy. Blood 2013;122:803-6. [PMID: 23733336 DOI: 10.1182/blood-2013-03-490060] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
7 Tironi-Farinati C, Geoghegan PA, Cangelosi A, Pinto A, Loidl CF, Goldstein J. A translational murine model of sub-lethal intoxication with Shiga toxin 2 reveals novel ultrastructural findings in the brain striatum. PLoS One 2013;8:e55812. [PMID: 23383285 DOI: 10.1371/journal.pone.0055812] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
8 Legros N, Dusny S, Humpf HU, Pohlentz G, Karch H, Müthing J. Shiga toxin glycosphingolipid receptors and their lipid membrane ensemble in primary human blood-brain barrier endothelial cells. Glycobiology 2017;27:99-109. [PMID: 27558838 DOI: 10.1093/glycob/cww090] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
9 Trachtman H. HUS and TTP in Children. Pediatr Clin North Am 2013;60:1513-26. [PMID: 24237985 DOI: 10.1016/j.pcl.2013.08.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 3.1] [Reference Citation Analysis]
10 Pérez L, Apezteguía L, Piñeyrúa C, Dabezies A, Bianco MN, Schelotto F, Varela G. Hemolytic uremic syndrome with mild renal involvement due to Shiga toxin-producing Escherichia coli (STEC) O145 strain. Rev Argent Microbiol 2014;46:103-6. [PMID: 25011592 DOI: 10.1016/S0325-7541(14)70056-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
11 Williams ME, Balogun RA. Principles of separation: indications and therapeutic targets for plasma exchange. Clin J Am Soc Nephrol 2014;9:181-90. [PMID: 24178973 DOI: 10.2215/CJN.04680513] [Cited by in Crossref: 39] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
12 Naïli I, Gardette M, Garrivier A, Daniel J, Desvaux M, Pizza M, Gobert A, Marchal T, Loukiadis E, Jubelin G. Interplay between enterohaemorrhagic Escherichia coli and nitric oxide during the infectious process. Emerg Microbes Infect 2020;9:1065-76. [PMID: 32459575 DOI: 10.1080/22221751.2020.1768804] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Keenswijk W, Raes A, Vande Walle J. Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence. Eur J Pediatr 2018;177:311-8. [PMID: 29288280 DOI: 10.1007/s00431-017-3077-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
14 D'Alessio L, Pinto A, Cangelosi A, Geoghegan PA, Tironi-Farinati C, Brener GJ, Goldstein J. Sub-Lethal Dose of Shiga Toxin 2 from Enterohemorrhagic Escherichia coli Affects Balance and Cerebellar Cytoarchitecture. Front Microbiol 2016;7:133. [PMID: 26904009 DOI: 10.3389/fmicb.2016.00133] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
15 Kurts C, Panzer U, Anders HJ, Rees AJ. The immune system and kidney disease: basic concepts and clinical implications. Nat Rev Immunol. 2013;13:738-753. [PMID: 24037418 DOI: 10.1038/nri3523] [Cited by in Crossref: 350] [Cited by in F6Publishing: 329] [Article Influence: 38.9] [Reference Citation Analysis]
16 Cheng LW, Henderson TD, Patfield S, Stanker LH, He X. Mouse in vivo neutralization of Escherichia coli Shiga toxin 2 with monoclonal antibodies. Toxins (Basel) 2013;5:1845-58. [PMID: 24152988 DOI: 10.3390/toxins5101845] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
17 Chui L, Patterson-Fortin L, Kuo J, Li V, Boras V. Evaluation of enzyme immunoassays and real-time PCR for detecting Shiga toxin-producing Escherichia coli in Southern Alberta, Canada. J Clin Microbiol 2015;53:1019-23. [PMID: 25588656 DOI: 10.1128/JCM.03288-14] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
18 Launders N, Byrne L, Jenkins C, Harker K, Charlett A, Adak GK. Disease severity of Shiga toxin-producing E. coli O157 and factors influencing the development of typical haemolytic uraemic syndrome: a retrospective cohort study, 2009-2012. BMJ Open 2016;6:e009933. [PMID: 26826153 DOI: 10.1136/bmjopen-2015-009933] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
19 Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8:643-657. [PMID: 23026949 DOI: 10.1038/nrneph.2012.214] [Cited by in Crossref: 349] [Cited by in F6Publishing: 291] [Article Influence: 34.9] [Reference Citation Analysis]
20 Keir LS, Saleem MA. Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome. Pediatr Nephrol 2014;29:1895-902. [PMID: 23843163 DOI: 10.1007/s00467-013-2561-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
21 Brocklebank V, Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J 2017;10:600-24. [PMID: 28980670 DOI: 10.1093/ckj/sfx081] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
22 Köckerling E, Karrasch L, Schweitzer A, Razum O, Krause G. Public Health Research Resulting from One of the World's Largest Outbreaks Caused by Entero-Hemorrhagic Escherichia coli in Germany 2011: A Review. Front Public Health 2017;5:332. [PMID: 29312915 DOI: 10.3389/fpubh.2017.00332] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
23 Jandhyala DM, Vanguri V, Boll EJ, Lai Y, McCormick BA, Leong JM. Shiga toxin-producing Escherichia coli O104:H4: an emerging pathogen with enhanced virulence. Infect Dis Clin North Am 2013;27:631-49. [PMID: 24011834 DOI: 10.1016/j.idc.2013.05.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
24 Keenswijk W, Raes A, De Clerck M, Vande Walle J. Is Plasma Exchange Efficacious in Shiga Toxin‐Associated Hemolytic Uremic Syndrome? A Narrative Review of Current Evidence. Ther Apher Dial 2018;23:118-25. [DOI: 10.1111/1744-9987.12768] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
25 Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019;34:171-354. [PMID: 31180581 DOI: 10.1002/jca.21705] [Cited by in Crossref: 314] [Cited by in F6Publishing: 277] [Article Influence: 104.7] [Reference Citation Analysis]
26 Watanabe-Takahashi M, Tamada M, Senda M, Hibino M, Shimizu E, Okuta A, Miyazawa A, Senda T, Nishikawa K. Identification of a peptide motif that potently inhibits two functionally distinct subunits of Shiga toxin. Commun Biol 2021;4:538. [PMID: 33972673 DOI: 10.1038/s42003-021-02068-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Li T, Tu W, Liu Y, Zhou P, Cai K, Li Z, Liu X, Ning N, Huang J, Wang S, Huang J, Wang H. A potential therapeutic peptide-based neutralizer that potently inhibits Shiga toxin 2 in vitro and in vivo. Sci Rep 2016;6:21837. [PMID: 26903273 DOI: 10.1038/srep21837] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
28 Kotimaa J, van der Pol P, Leijtens S, Klar-mohammad N, Schilders G, Daha M, Rutjes H, van Kooten C. Functional assessment of rat complement pathway activities and quantification of soluble C5b-9 in an experimental model of renal ischemia/reperfusion injury. Journal of Immunological Methods 2014;412:14-23. [DOI: 10.1016/j.jim.2014.06.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
29 Matsushima A, Oda K, Mori N, Murakami T. Modulation of multidrug resistance-associated proteins function in erythrocytes in glycerol-induced acute renal failure rats. Journal of Pharmacy and Pharmacology 2017;69:172-81. [DOI: 10.1111/jphp.12664] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
30 Harkins VJ, Mcallister DA, Reynolds BC. Shiga-Toxin E. coli Hemolytic Uremic Syndrome: Review of Management and Long-term Outcome. Curr Pediatr Rep 2020;8:16-25. [DOI: 10.1007/s40124-020-00208-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
31 Nguyen TC. Thrombocytopenia-Associated Multiple Organ Failure. Crit Care Clin 2020;36:379-90. [PMID: 32172819 DOI: 10.1016/j.ccc.2019.12.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
32 Melton-celsa AR, O'brien AD, Sperandio V, Hovde CJ. New Therapeutic Developments against Shiga Toxin-Producing Escherichia coli. Microbiol Spectr 2014;2. [DOI: 10.1128/microbiolspec.ehec-0013-2013] [Cited by in Crossref: 38] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
33 Shi C, Li C, Ye W, Ye WL, Li MX. Nephrotic-range proteinuria and central nervous involvement in typical hemolytic uremic syndrome: a case report. BMC Nephrol 2020;21:319. [PMID: 32736529 DOI: 10.1186/s12882-020-01979-3] [Reference Citation Analysis]
34 Radhakrishnan ST, Ruban A, Uthayakumar AK, Cohen P, Levy J, Teare J. Haemolytic uraemic syndrome - a rare case report of bloody diarrhoea in adults. BMC Gastroenterol 2019;19:156. [PMID: 31462210 DOI: 10.1186/s12876-019-1071-4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Bauer A, Loos S, Wehrmann C, Horstmann D, Donnerstag F, Lemke J, Hillebrand G, Löbel U, Pape L, Haffner D, Bindt C, Ahlenstiel T, Melk A, Lehnhardt A, Kemper MJ, Oh J, Hartmann H. Neurological involvement in children with E. coli O104:H4-induced hemolytic uremic syndrome. Pediatr Nephrol 2014;29:1607-15. [PMID: 24664191 DOI: 10.1007/s00467-014-2803-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
36 Karve SS, Weiss AA. Glycolipid binding preferences of Shiga toxin variants. PLoS One 2014;9:e101173. [PMID: 24983355 DOI: 10.1371/journal.pone.0101173] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
37 Malov VA, Maleev VV, Kozlovskaya NL, Tsvetkova NA, Smetanina SV, Gorobchenko AN, Serova VV, Chentsov VB, Volkov AG, Faller AP. [Difficulties in the diagnosis of diarrhea-associated hemolytic uremic syndrome in adults]. Ter Arkh 2017;89:69-78. [PMID: 29260749 DOI: 10.17116/terarkh2017891169-78] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Ozuru R, Wakao S, Tsuji T, Ohara N, Matsuba T, Amuran MY, Isobe J, Iino M, Nishida N, Matsumoto S, Iwadate K, Konishi N, Yasuda K, Tashiro K, Hida M, Yadoiwa A, Kato S, Yamashita E, Matsumoto S, Kurozawa Y, Dezawa M, Fujii J. Rescue from Stx2-Producing E. coli-Associated Encephalopathy by Intravenous Injection of Muse Cells in NOD-SCID Mice. Mol Ther 2020;28:100-18. [PMID: 31607541 DOI: 10.1016/j.ymthe.2019.09.023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
39 Vaterodt L, Holle J, Hüseman D, Müller D, Thumfart J. Short- and Long-Term Renal Outcome of Hemolytic-Uremic Syndrome in Childhood. Front Pediatr 2018;6:220. [PMID: 30131950 DOI: 10.3389/fped.2018.00220] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
40 Bitzan M, Lapeyraque A. Postinfectious Hemolytic Uremic Syndrome. In: Geary DF, Schaefer F, editors. Pediatric Kidney Disease. Berlin: Springer Berlin Heidelberg; 2016. pp. 653-731. [DOI: 10.1007/978-3-662-52972-0_26] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
41 Adamski J. Thrombotic microangiopathy and indications for therapeutic plasma exchange. Hematology 2014;2014:444-9. [DOI: 10.1182/asheducation-2014.1.444] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
42 Steil D, Bonse R, Meisen I, Pohlentz G, Vallejo G, Karch H, Müthing J. A Topographical Atlas of Shiga Toxin 2e Receptor Distribution in the Tissues of Weaned Piglets. Toxins (Basel) 2016;8:E357. [PMID: 27916888 DOI: 10.3390/toxins8120357] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
43 Wijnsma KL, Schijvens AM, Rossen JWA, Kooistra-Smid AMDM, Schreuder MF, van de Kar NCAJ. Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing E. coli O80:H2. Pediatr Nephrol 2017;32:1263-8. [PMID: 28343354 DOI: 10.1007/s00467-017-3642-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
44 Platnich JM, Chung H, Lau A, Sandall CF, Bondzi-Simpson A, Chen HM, Komada T, Trotman-Grant AC, Brandelli JR, Chun J, Beck PL, Philpott DJ, Girardin SE, Ho M, Johnson RP, MacDonald JA, Armstrong GD, Muruve DA. Shiga Toxin/Lipopolysaccharide Activates Caspase-4 and Gasdermin D to Trigger Mitochondrial Reactive Oxygen Species Upstream of the NLRP3 Inflammasome. Cell Rep 2018;25:1525-1536.e7. [PMID: 30404007 DOI: 10.1016/j.celrep.2018.09.071] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 18.0] [Reference Citation Analysis]
45 Nguyen TC, Cruz MA, Carcillo JA. Thrombocytopenia-Associated Multiple Organ Failure and Acute Kidney Injury. Crit Care Clin 2015;31:661-74. [PMID: 26410136 DOI: 10.1016/j.ccc.2015.06.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.1] [Reference Citation Analysis]
46 Menne J, Kielstein J, Wenzel U, Stahl R. Therapie des typischen hämolytisch-urämischen Syndroms: Erkenntnisse aus dem E.-coli-Ausbruch 2011. Internist 2012;53:1420-30. [DOI: 10.1007/s00108-012-3107-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
47 Kavanagh D, Raman S, Sheerin NS. Management of hemolytic uremic syndrome. F1000Prime Rep 2014;6:119. [PMID: 25580273 DOI: 10.12703/P6-119] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
48 Ko H, Maymani H, Rojas-Hernandez C. Hemolytic uremic syndrome associated with Escherichia coli O157:H7 infection in older adults: a case report and review of the literature. J Med Case Rep 2016;10:175. [PMID: 27301547 DOI: 10.1186/s13256-016-0970-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
49 Lingwood C. Verotoxin Receptor-Based Pathology and Therapies. Front Cell Infect Microbiol 2020;10:123. [PMID: 32296648 DOI: 10.3389/fcimb.2020.00123] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
50 Kehl A, Kuhn R, Detzner J, Steil D, Müthing J, Karch H, Mellmann A. Modeling Native EHEC Outer Membrane Vesicles by Creating Synthetic Surrogates. Microorganisms 2020;8:E673. [PMID: 32384757 DOI: 10.3390/microorganisms8050673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Costigan C, Raftery T, Carroll AG, Wildes D, Reynolds C, Cunney R, Dolan N, Drew RJ, Lynch BJ, O'Rourke DJ, Stack M, Sweeney C, Shahwan A, Twomey E, Waldron M, Riordan M, Awan A, Gorman KM. Neurological involvement in children with hemolytic uremic syndrome. Eur J Pediatr 2021. [PMID: 34378062 DOI: 10.1007/s00431-021-04200-1] [Reference Citation Analysis]
52 Gavriilaki E, Yuan X, Ye Z, Ambinder AJ, Shanbhag SP, Streiff MB, Kickler TS, Moliterno AR, Sperati CJ, Brodsky RA. Modified Ham test for atypical hemolytic uremic syndrome. Blood 2015;125:3637-46. [PMID: 25862562 DOI: 10.1182/blood-2015-02-629683] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 9.1] [Reference Citation Analysis]
53 Joseph A, Cointe A, Mariani Kurkdjian P, Rafat C, Hertig A. Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review. Toxins (Basel) 2020;12:E67. [PMID: 31973203 DOI: 10.3390/toxins12020067] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 16.0] [Reference Citation Analysis]
54 Hücker SM, Ardern Z, Goldberg T, Schafferhans A, Bernhofer M, Vestergaard G, Nelson CW, Schloter M, Rost B, Scherer S, Neuhaus K. Discovery of numerous novel small genes in the intergenic regions of the Escherichia coli O157:H7 Sakai genome. PLoS One 2017;12:e0184119. [PMID: 28902868 DOI: 10.1371/journal.pone.0184119] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.6] [Reference Citation Analysis]
55 Exeni RA, Fernandez-Brando RJ, Santiago AP, Fiorentino GA, Exeni AM, Ramos MV, Palermo MS. Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol 2018;33:2057-71. [PMID: 29372302 DOI: 10.1007/s00467-017-3876-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
56 Hosaka T, Nakamagoe K, Tamaoka A. Hemolytic Uremic Syndrome-associated Encephalopathy Successfully Treated with Corticosteroids. Intern Med 2017;56:2937-41. [PMID: 28943538 DOI: 10.2169/internalmedicine.8341-16] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Pirolli NH, Bentley WE, Jay SM. Bacterial Extracellular Vesicles and the Gut-Microbiota Brain Axis: Emerging Roles in Communication and Potential as Therapeutics. Adv Biol (Weinh) 2021;5:e2000540. [PMID: 33857347 DOI: 10.1002/adbi.202000540] [Reference Citation Analysis]
58 Joob B, Wiwanitkit V. Cancerous patients and outbreak of Escherichia coli: an important issue in oncology. Asian Pacific Journal of Tropical Disease 2014;4:204-6. [DOI: 10.1016/s2222-1808(14)60506-5] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
59 Bruyand M, Mariani-Kurkdjian P, Gouali M, de Valk H, King LA, Le Hello S, Bonacorsi S, Loirat C. Hemolytic uremic syndrome due to Shiga toxin-producing Escherichia coli infection. Med Mal Infect 2018;48:167-74. [PMID: 29054297 DOI: 10.1016/j.medmal.2017.09.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
60 Ruano-Gallego D, Yara DA, Di Ianni L, Frankel G, Schüller S, Fernández LÁ. A nanobody targeting the translocated intimin receptor inhibits the attachment of enterohemorrhagic E. coli to human colonic mucosa. PLoS Pathog 2019;15:e1008031. [PMID: 31465434 DOI: 10.1371/journal.ppat.1008031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
61 Chakraborty D, Clark E, Mauro SA, Koudelka GB. Molecular Mechanisms Governing "Hair-Trigger" Induction of Shiga Toxin-Encoding Prophages. Viruses 2018;10:E228. [PMID: 29710828 DOI: 10.3390/v10050228] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
62 Jenssen GR, Vold L, Hovland E, Bangstad HJ, Nygård K, Bjerre A. Clinical features, therapeutic interventions and long-term aspects of hemolytic-uremic syndrome in Norwegian children: a nationwide retrospective study from 1999-2008. BMC Infect Dis 2016;16:285. [PMID: 27297224 DOI: 10.1186/s12879-016-1627-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
63 Bernedo-Navarro RA, Miyachiro MM, da Silva MJ, Reis CF, Conceição RA, Gatti MS, Yano T. Peptides derived from phage display libraries as potential neutralizers of Shiga toxin-induced cytotoxicity in vitro and in vivo. J Appl Microbiol 2014;116:1322-33. [PMID: 24447276 DOI: 10.1111/jam.12451] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
64 Goldstein J, Nuñez-Goluboay K, Pinto A. Therapeutic Strategies to Protect the Central Nervous System against Shiga Toxin from Enterohemorrhagic Escherichia coli. Curr Neuropharmacol 2021;19:24-44. [PMID: 32077828 DOI: 10.2174/1570159X18666200220143001] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
65 Fang Y, McMullen LM, Gänzle MG. Effect of drying on oxidation of membrane lipids and expression of genes encoded by the Shiga toxin prophage in Escherichia coli. Food Microbiol 2020;86:103332. [PMID: 31703888 DOI: 10.1016/j.fm.2019.103332] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
66 Kouzel IU, Kehl A, Berger P, Liashkovich I, Steil D, Makalowski W, Suzuki Y, Pohlentz G, Karch H, Mellmann A, Müthing J. RAB5A and TRAPPC6B are novel targets for Shiga toxin 2a inactivation in kidney epithelial cells. Sci Rep 2020;10:4945. [PMID: 32188865 DOI: 10.1038/s41598-020-59694-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
67 Hauswaldt S, Nitschke M, Sayk F, Solbach W, Knobloch JK. Lessons Learned From Outbreaks of Shiga Toxin Producing Escherichia coli. Curr Infect Dis Rep 2013;15:4-9. [PMID: 23212721 DOI: 10.1007/s11908-012-0302-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
68 Mitsui T, Watanabe-Takahashi M, Shimizu E, Zhang B, Funamoto S, Yamasaki S, Nishikawa K. Affinity-Based Screening of Tetravalent Peptides Identifies Subtype-Selective Neutralizers of Shiga Toxin 2d, a Highly Virulent Subtype, by Targeting a Unique Amino Acid Involved in Its Receptor Recognition. Infect Immun 2016;84:2653-61. [PMID: 27382021 DOI: 10.1128/IAI.00149-16] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
69 Canpolat N. Hemolytic uremic syndrome. Turk Pediatri Ars 2015;50:73-82. [PMID: 26265890 DOI: 10.5152/tpa.2015.2297] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
70 Verhave JC, Wetzels JF, van de Kar NC. Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab. Nephrol Dial Transplant 2014;29 Suppl 4:iv131-41. [PMID: 25165180 DOI: 10.1093/ndt/gfu235] [Cited by in Crossref: 46] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
71 Risitano AM. Current and Future Pharmacologic Complement Inhibitors. Hematology/Oncology Clinics of North America 2015;29:561-82. [DOI: 10.1016/j.hoc.2015.01.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
72 Kato M, Watanabe-Takahashi M, Shimizu E, Nishikawa K. Identification of a wide range of motifs inhibitory to shiga toxin by affinity-driven screening of customized divalent peptides synthesized on a membrane. Appl Environ Microbiol 2015;81:1092-100. [PMID: 25452283 DOI: 10.1128/AEM.03517-14] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
73 Monet-Didailler C, Chevallier A, Godron-Dubrasquet A, Allard L, Delmas Y, Contin-Bordes C, Brissaud O, Llanas B, Harambat J. Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study. Nephrol Dial Transplant 2020;35:2147-53. [PMID: 31411695 DOI: 10.1093/ndt/gfz158] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
74 Roumenina LT, Rayes J, Frimat M, Fremeaux-Bacchi V. Endothelial cells: source, barrier, and target of defensive mediators. Immunol Rev 2016;274:307-29. [PMID: 27782324 DOI: 10.1111/imr.12479] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 10.8] [Reference Citation Analysis]
75 Khalid M, Andreoli S. Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS). Pediatr Nephrol 2019;34:2495-507. [PMID: 30382336 DOI: 10.1007/s00467-018-4105-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
76 Pradhan S, Pellino C, MacMaster K, Coyle D, Weiss AA. Shiga Toxin Mediated Neurologic Changes in Murine Model of Disease. Front Cell Infect Microbiol 2016;6:114. [PMID: 27747196 DOI: 10.3389/fcimb.2016.00114] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
77 Lee MS, Tesh VL. Roles of Shiga Toxins in Immunopathology. Toxins (Basel) 2019;11:E212. [PMID: 30970547 DOI: 10.3390/toxins11040212] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 10.3] [Reference Citation Analysis]
78 Ekinci Z, Bek K, Aytac MB, Karadenizli A, Hancer VS. Renal outcome with eculizumab in two diarrhea-associated hemolytic–uremic syndrome cases with severe neurologic involvement. Hong Kong Journal of Nephrology 2014;16:46-9. [DOI: 10.1016/j.hkjn.2014.07.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
79 Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, Dunbar NM, Witt V, Wu Y, Shaz BH. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher. 2016;31:149-162. [PMID: 27322218 DOI: 10.1002/jca.21470] [Cited by in Crossref: 168] [Cited by in F6Publishing: 216] [Article Influence: 33.6] [Reference Citation Analysis]
80 Detzner J, Pohlentz G, Müthing J. Valid Presumption of Shiga Toxin-Mediated Damage of Developing Erythrocytes in EHEC-Associated Hemolytic Uremic Syndrome. Toxins (Basel) 2020;12:E373. [PMID: 32512916 DOI: 10.3390/toxins12060373] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
81 Santangelo L, Netti GS, Torres DD, Piscopo G, Carbone V, Losito L, Milella L, Lasorella ML, Conti P, Gagliardi D, Chironna M, Spadaccino F, Bresin E, Trabacca A, Ranieri E, Giordano M. Peripheral nervous system manifestations of Shiga toxin-producing E. coli-induced haemolytic uremic syndrome in children. Ital J Pediatr 2021;47:181. [PMID: 34488831 DOI: 10.1186/s13052-021-01133-1] [Reference Citation Analysis]
82 Turner N, Sartain S, Moake J. Ultralarge von Willebrand factor-induced platelet clumping and activation of the alternative complement pathway in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndromes.Hematol Oncol Clin North Am. 2015;29:509-524. [PMID: 26043389 DOI: 10.1016/j.hoc.2015.01.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
83 Braune SA, Wichmann D, von Heinz MC, Nierhaus A, Becker H, Meyer TN, Meyer GP, Müller-Schulz M, Fricke J, de Weerth A, Hoepker WW, Fiehler J, Magnus T, Gerloff C, Panzer U, Stahl RA, Wegscheider K, Kluge S. Clinical features of critically ill patients with Shiga toxin-induced hemolytic uremic syndrome. Crit Care Med 2013;41:1702-10. [PMID: 23660733 DOI: 10.1097/CCM.0b013e31828a24a8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
84 Frémeaux-Bacchi V. [Pathophysiology of atypical hemolytic uremic syndrome. Ten years of progress, from laboratory to patient]. Biol Aujourdhui 2013;207:231-40. [PMID: 24594571 DOI: 10.1051/jbio/2013027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
85 Rasa M, Musgrave J, Abe K, Tanaka L, Xoinis K, Shiramizu B, Foskett G, Lau R. A Case of Escherichia coli Hemolytic Uremic Syndrome in a 10-Year-Old Male With Severe Neurologic Involvement Successfully Treated With Eculizumab. J Investig Med High Impact Case Rep 2017;5:2324709617741144. [PMID: 29152520 DOI: 10.1177/2324709617741144] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
86 Gitiaux C, Krug P, Grevent D, Kossorotoff M, Poncet S, Eisermann M, Oualha M, Boddaert N, Salomon R, Desguerre I. Brain magnetic resonance imaging pattern and outcome in children with haemolytic-uraemic syndrome and neurological impairment treated with eculizumab. Dev Med Child Neurol 2013;55:758-65. [PMID: 23659643 DOI: 10.1111/dmcn.12161] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
87 Giordano P, Netti GS, Santangelo L, Castellano G, Carbone V, Torres DD, Martino M, Sesta M, Di Cuonzo F, Resta MC, Gaeta A, Milella L, Chironna M, Germinario C, Scavia G, Gesualdo L, Giordano M. A pediatric neurologic assessment score may drive the eculizumab-based treatment of Escherichia coli-related hemolytic uremic syndrome with neurological involvement. Pediatr Nephrol 2019;34:517-27. [PMID: 30362078 DOI: 10.1007/s00467-018-4112-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
88 Vera-Aguilera J, Duma N, Gast K, Alkhateeb H, Tande A, Leung N, Hogan WJ, Kenderian SJ. Hemolytic Uremic Syndrome Associated With Escherichia coli O157 Infection in an Allogenic Stem Cell Transplant Recipient. Mayo Clin Proc Innov Qual Outcomes 2018;2:387-91. [PMID: 30560242 DOI: 10.1016/j.mayocpiqo.2018.07.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
89 Steil D, Schepers CL, Pohlentz G, Legros N, Runde J, Humpf HU, Karch H, Müthing J. Shiga toxin glycosphingolipid receptors of Vero-B4 kidney epithelial cells and their membrane microdomain lipid environment. J Lipid Res 2015;56:2322-36. [PMID: 26464281 DOI: 10.1194/jlr.M063040] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
90 NATIONAL ADVISORY COMMITTEE ON MICROBIOLOGICAL CRITERIA FOR FOODS. Response to Questions Posed by the Food and Drug Administration Regarding Virulence Factors and Attributes that Define Foodborne Shiga Toxin-Producing Escherichia coli (STEC) as Severe Human Pathogens . J Food Prot 2019;82:724-67. [PMID: 30969806 DOI: 10.4315/0362-028X.JFP-18-479] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
91 Pradel N, Etienne-Mesmin L, Thévenot J, Cordonnier C, Blanquet-Diot S, Livrelli V. In vitro adhesion properties of Shiga toxin-producing Escherichia coli isolated from cattle, food, and humans. Front Microbiol 2015;6:156. [PMID: 25774152 DOI: 10.3389/fmicb.2015.00156] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
92 Boisen N, Hansen AM, Melton-Celsa AR, Zangari T, Mortensen NP, Kaper JB, O'Brien AD, Nataro JP. The presence of the pAA plasmid in the German O104:H4 Shiga toxin type 2a (Stx2a)-producing enteroaggregative Escherichia coli strain promotes the translocation of Stx2a across an epithelial cell monolayer. J Infect Dis 2014;210:1909-19. [PMID: 25038258 DOI: 10.1093/infdis/jiu399] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
93 da Silva PSL, Lipinski RW. Hemolytic uremic syndrome associated with Acinetobacter hemolyticus. Renal Failure 2014;36:1122-4. [DOI: 10.3109/0886022x.2014.917575] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
94 Mounier S, Gavotto A, Tenenbaum J, Meyer P, Fila M, Baleine J. Hemolytic uremic syndrome related to Shiga-like toxin-producing Escherichia coli with encephalitis hiding a human herpesvirus-6 infection: a case report. J Med Case Rep 2021;15:300. [PMID: 34034812 DOI: 10.1186/s13256-021-02873-8] [Reference Citation Analysis]
95 Legros N, Pohlentz G, Steil D, Kouzel IU, Liashkovich I, Mellmann A, Karch H, Müthing J. Membrane assembly of Shiga toxin glycosphingolipid receptors and toxin refractiveness of MDCK II epithelial cells. J Lipid Res 2018;59:1383-401. [PMID: 29866658 DOI: 10.1194/jlr.M083048] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
96 Yıldız S, Demirkan F. What is the evidence for the role of therapeutic apheresis in the management of complement-associated thrombotic microangiopathies? Transfus Apher Sci 2018;57:31-4. [PMID: 29506907 DOI: 10.1016/j.transci.2018.02.013] [Reference Citation Analysis]
97 Flam B, Sackey P, Berge A, Zachau AC, Brink B, Lundberg S. Diarrhea-associated hemolytic uremic syndrome with severe neurological manifestations treated with IgG depletion through immunoadsorption. J Nephrol 2016;29:711-4. [PMID: 26995001 DOI: 10.1007/s40620-016-0294-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
98 Porubsky S, Federico G, Müthing J, Jennemann R, Gretz N, Büttner S, Obermüller N, Jung O, Hauser IA, Gröne E, Geiger H, Gröne HJ, Betz C. Direct acute tubular damage contributes to Shigatoxin-mediated kidney failure. J Pathol 2014;234:120-33. [PMID: 24909663 DOI: 10.1002/path.4388] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 4.9] [Reference Citation Analysis]
99 Moxley RA, Francis DH, Tamura M, Marx DB, Santiago-Mateo K, Zhao M. Efficacy of Urtoxazumab (TMA-15 Humanized Monoclonal Antibody Specific for Shiga Toxin 2) Against Post-Diarrheal Neurological Sequelae Caused by Escherichia coli O157:H7 Infection in the Neonatal Gnotobiotic Piglet Model. Toxins (Basel) 2017;9:E49. [PMID: 28134751 DOI: 10.3390/toxins9020049] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
100 Tran SL, Jenkins C, Livrelli V, Schüller S. Shiga toxin 2 translocation across intestinal epithelium is linked to virulence of Shiga toxin-producing Escherichia coli in humans. Microbiology (Reading) 2018;164:509-16. [PMID: 29533744 DOI: 10.1099/mic.0.000645] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
101 Muff-Luett M, Sanderson KR, Engen RM, Zahr RS, Wenderfer SE, Tran CL, Sharma S, Cai Y, Ingraham S, Winnicki E, Weaver DJ, Hunley TE, Kiessling SG, Seamon M, Woroniecki R, Miyashita Y, Xiao N, Omoloja AA, Kizilbash SJ, Mansuri A, Kallash M, Yu Y, Sherman AK, Srivastava T, Nester CM. Eculizumab exposure in children and young adults: indications, practice patterns, and outcomes-a Pediatric Nephrology Research Consortium study. Pediatr Nephrol 2021;36:2349-60. [PMID: 33693990 DOI: 10.1007/s00467-021-04965-5] [Reference Citation Analysis]
102 Detzner J, Krojnewski E, Pohlentz G, Steil D, Humpf HU, Mellmann A, Karch H, Müthing J. Shiga Toxin (Stx)-Binding Glycosphingolipids of Primary Human Renal Cortical Epithelial Cells (pHRCEpiCs) and Stx-Mediated Cytotoxicity. Toxins (Basel) 2021;13:139. [PMID: 33673393 DOI: 10.3390/toxins13020139] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
103 Hua Y, Chromek M, Frykman A, Jernberg C, Georgieva V, Hansson S, Zhang J, Marits AK, Wan C, Matussek A, Bai X. Whole-genome characterization of hemolytic uremic syndrome-causing Shiga toxin-producing Escherichia coli in Sweden. Virulence 2021;12:1296-305. [PMID: 33939581 DOI: 10.1080/21505594.2021.1922010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
104 Tavasoli A, Zafaranloo N, Hoseini R, Otukesh H, Nakhaiee S. Frequency of neurological involvement in patients with/without diarrhea hemolytic uremic syndrome: A Systematic review and meta-analysis. Med J Islam Repub Iran 2021;35:91. [PMID: 34956937 DOI: 10.47176/mjiri.35.91] [Reference Citation Analysis]
105 Tome J, Maselli DB, Im R, Amdahl MB, Pfeifle D, Hagen C, Halland M. A case of hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli after pericardiectomy. Clin J Gastroenterol 2021. [PMID: 34677733 DOI: 10.1007/s12328-021-01539-8] [Reference Citation Analysis]
106 Cha W, Fratamico PM, Ruth LE, Bowman AS, Nolting JM, Manning SD, Funk JA. Prevalence and characteristics of Shiga toxin-producing Escherichia coli in finishing pigs: Implications on public health. International Journal of Food Microbiology 2018;264:8-15. [DOI: 10.1016/j.ijfoodmicro.2017.10.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
107 Pape L, Hartmann H, Bange FC, Suerbaum S, Bueltmann E, Ahlenstiel-Grunow T. Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement. Medicine (Baltimore) 2015;94:e1000. [PMID: 26091445 DOI: 10.1097/MD.0000000000001000] [Cited by in Crossref: 56] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
108 Sandvig K, Bergan J, Kavaliauskiene S, Skotland T. Lipid requirements for entry of protein toxins into cells. Prog Lipid Res 2014;54:1-13. [PMID: 24462587 DOI: 10.1016/j.plipres.2014.01.001] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 7.3] [Reference Citation Analysis]
109 Brown CC, Garcia X, Bhakta RT, Sanders E, Prodhan P. Severe Acute Neurologic Involvement in Children With Hemolytic-Uremic Syndrome. Pediatrics 2021;147:e2020013631. [PMID: 33579812 DOI: 10.1542/peds.2020-013631] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
110 McCarthy SC, Burgess CM, Fanning S, Duffy G. An Overview of Shiga-Toxin Producing Escherichia coli Carriage and Prevalence in the Ovine Meat Production Chain. Foodborne Pathog Dis 2021;18:147-68. [PMID: 33395551 DOI: 10.1089/fpd.2020.2861] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Lo NC, Turner NA, Cruz MA, Moake J. Interaction of Shiga toxin with the A-domains and multimers of von Willebrand Factor. J Biol Chem 2013;288:33118-23. [PMID: 24097977 DOI: 10.1074/jbc.M113.487413] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
112 Hews CL, Tran SL, Wegmann U, Brett B, Walsham ADS, Kavanaugh D, Ward NJ, Juge N, Schüller S. The StcE metalloprotease of enterohaemorrhagic Escherichia coli reduces the inner mucus layer and promotes adherence to human colonic epithelium ex vivo. Cell Microbiol 2017;19. [PMID: 28054754 DOI: 10.1111/cmi.12717] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
113 Chui L, Li V, Fach P, Delannoy S, Malejczyk K, Patterson-Fortin L, Poon A, King R, Simmonds K, Scott AN, Lee MC. Molecular profiling of Escherichia coli O157:H7 and non-O157 strains isolated from humans and cattle in Alberta, Canada. J Clin Microbiol 2015;53:986-90. [PMID: 25540392 DOI: 10.1128/JCM.03321-14] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
114 Ibarra C, Amaral MM, Palermo MS. Advances in pathogenesis and therapy of hemolytic uremic syndrome caused by Shiga toxin-2. IUBMB Life 2013;65:827-35. [PMID: 24014500 DOI: 10.1002/iub.1206] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
115 Petruzziello-Pellegrini TN, Moslemi-Naeini M, Marsden PA. New insights into Shiga toxin-mediated endothelial dysfunction in hemolytic uremic syndrome. Virulence 2013;4:556-63. [PMID: 23955166 DOI: 10.4161/viru.26143] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
116 Borkar D, Schutt C, Verghese P. Renal Recovery Years After Initial Diagnosis of Hemolytic Uremic Syndrome. Clin Pediatr (Phila) 2018;57:861-4. [PMID: 28931327 DOI: 10.1177/0009922817732621] [Reference Citation Analysis]
117 Ylinen E, Salmenlinna S, Halkilahti J, Jahnukainen T, Korhonen L, Virkkala T, Rimhanen-Finne R, Nuutinen M, Kataja J, Arikoski P, Linkosalo L, Bai X, Matussek A, Jalanko H, Saxén H. Hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli in children: incidence, risk factors, and clinical outcome. Pediatr Nephrol 2020;35:1749-59. [PMID: 32323005 DOI: 10.1007/s00467-020-04560-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]